Anavex Life Sciences Corp. · NASDAQ:AVXL

Anavex Life Sciences — 2016 Rett Syndrome Symposium

30 slides from Anavex Life Sciences's conference presentation, June 2016

  1. Slide 1: Rettsyndrome.org Research Symposium 2016

    Slide 1: Rettsyndrome.org Research Symposium 2016

    Wo ulti ‘an Wy” I} | Gat wi 2 UNITY-STRENGTH~HVPE RETTSYNDROME.ORG « EAGLEWOOD RESORT, ILLINOIS * 2016 RESEARCH SYMPOSIUM (JUNE 22-24) Nothing ceplaces the experience of meeting face-to-face 14th Rettsyndrome.org Rett Syndrome Symposium, an international, interdisciplinary meeting focused on recent

  2. Slide 2: ANAVEX 2-73 as a Potential Treatment for Rett Syndrome and Other Pediatric Disorders

    Slide 2: ANAVEX 2-73 as a Potential Treatment for Rett Syndrome and Other Pediatric Disorders

    ANAVEX 2-­‐73 as a Poten2al Treatment for Re9 Syndrome and Other Pediatric or Infan2le Disorders with Seizure Pathology N. REBOWE1, J SPROUSE1, D. BRUNNER2, P. KABITZKE2, L. VELISEK3, M. BENSON3, J. VELISKOVA3, C. MISSLING1 1Anavex Life Sciences, New York, NY; 2Psychogenics, Tarrytown, NY; 3New York

  3. Slide 3: Disclosure

    Slide 3: Disclosure

    Disclosure § Employee of Anavex Life Sciences § Shareholder of Anavex Life Sciences § Op8ons of Anavex Life Sciences 3

  4. Slide 4: Safe Harbor

    Slide 4: Safe Harbor

    Safe Harbor This presenta8on contains forward-­‐looking statements made within the meaning of the Private Securi8es Li8ga8on Reform Act of 1995 by Anavex™ Life Sciences Corp. and its representa8ves. These statements can be iden8fied by introductory words such as ``expects,'' ``plans,'' ``intends,'' `

  5. Slide 5: ANAVEX 2-73

    Slide 5: ANAVEX 2-73

    ANAVEX™ 2-­‐73 § Currently in a Phase 2a clinical trial for Alzheimer’s disease (AD) § ANAVEX 2-­‐73 is an orally available small molecule targe8ng protein misfolding, oxida8ve stress, mitochondrial dysfunc8on, inflamma8on and cellular stress, factors in neurodegenera2ve and neurodevelopmental dise

  6. Slide 6: Sigma-1 Receptor: Upstream Pluripotent Modulator

    Slide 6: Sigma-1 Receptor: Upstream Pluripotent Modulator

    Sigma-­‐1 Receptor: Upstream Pluripotent Modulator § Reducing mitochondrial dysfunc8on § Reducing oxida8ve stress § Reducing protein misfolding § Reducing inflamma8on § Modula8ng Ca2+ § Enabling neuroprotec8on Su et al., Trends Pharmacol Sci. 2016 Feb 8. pii: S0165-­‐6147(16)00004-­‐3; Cauli et

  7. Slide 7: ER-Mitochondria Axis Disruption; Sigma-1R Restores Association

    Slide 7: ER-Mitochondria Axis Disruption; Sigma-1R Restores Association

    Common in Neurodegenera2ve Diseases: ER-­‐Mitochondria Axis Disrup2on … Sigma-­‐1R Restores Associa2on … Disease situa8on Normal situa8on ER Mitochondrion S1R ANAVEX 2-73 ANAVEX 2-73 Endoplasmic re8culum (ER)-­‐Mitochondria associa8ons are disrupted in neurodegenera8ve diseases …# … Sigma-­‐1R resto

  8. Slide 8: Mitochondrial Dysfunction in Neurodevelopmental and Neurodegenerative Diseases

    Slide 8: Mitochondrial Dysfunction in Neurodevelopmental and Neurodegenerative Diseases

    Mitochondrial Dysfunc2on: Convergence of Pathological and Gene2c Lesions in Neurodevelopmental and Neurodegenera2ve Diseases 8 Sources: Vacca et al. Neuroscience and Biobehavioral Reviews 46 (2014) 202–217; Miller et al. Trends in Neurosciences, March 2016, Vol. 39, No. 3

  9. Slide 9: ANAVEX 2-73: Confirmed Targeted Indications

    Slide 9: ANAVEX 2-73: Confirmed Targeted Indications

    ANAVEX™ 2-­‐73: Confirmed Targeted Indica2ons: From Rare Disease Indica2ons to Largest CNS Indica2on … Re9 Syndrome (RTT) Alzheimer’s Disease (AD) Rare neurodevelopmental disease Neurodegenera8ve disease Preclinical valida8on, RePSyndrome.org þ Clinical valida8on Phase 2a þ Planning blinded control

  10. Slide 10: Neurodevelopmental and Neurodegenerative Disease Pipeline

    Slide 10: Neurodevelopmental and Neurodegenerative Disease Pipeline

    Neurodevelopmental and Neurodegenera2ve Disease Pipeline ANAVEX™ 2-73 PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ALZHEIMER’S COGNITION IN NEUROPSYCHIATRIC EPILEPSY PARKINSON’S MULTIPLE SCLEROSIS (MS) RARE DISEASE, FRAGILE X RARE DISEASE, RETT SYNDROME RARE DISEASE, INFANTILE SPASMS ANAVEX™ 3-71 (AF710B) RA

  11. Slide 11: ANAVEX 2-73 Pre-Clinical Epilepsy Data

    Slide 11: ANAVEX 2-73 Pre-Clinical Epilepsy Data

    ANAVEX™ 2-­‐73 Pre-­‐Clinical Epilepsy Data Significant Seizure Reduc8on with ANAVEX2-­‐73 in Long-­‐Las8ng Effect Shown in PTZ-­‐ both MES and PTZ-­‐Induced Seizure Models Induced Seizures *** *** *** *** 100 *** *** 100 90 *** p<0.001 90 80 MES-­‐induced 80 convulsions # % of Seizure reduc2on % of S

  12. Slide 12: Anti-Depressant and Anti-Anxiety Effect of ANAVEX 2-73

    Slide 12: Anti-Depressant and Anti-Anxiety Effect of ANAVEX 2-73

    An2-­‐Depressant and An2-­‐Anxiety Effect of ANAVEX™ 2-­‐73 in Porsolt Swim Test (PST) and in Open Field Test No observed “seda2ve” effect of ANAVEX 2-­‐73 § Effect of ANAVEX2-­‐73 on immobility 8me on § Effect of ANAVEX2-­‐73 on the number of PST. P<0.01, *p<0.05 and **p<0.01 for 50 and crosses (mo8l

  13. Slide 13: Autism Spectrum Disorders and Fragile X Syndrome

    Slide 13: Autism Spectrum Disorders and Fragile X Syndrome

    Au2sm Spectrum Disorders and Fragile X Syndrome § Au8sm spectrum disorders (ASD) occur in up to 2/3 of males and 1/3 of females with Fragile X syndrome (FXS) § FXS is the most common form of inherited intellectual disability and the most frequent single gene cause of au8sm, affec8ng approximately 1

  14. Slide 14: ANAVEX 2-73 Reverses Hyperactivity and Learning Deficits in Fragile X Model

    Slide 14: ANAVEX 2-73 Reverses Hyperactivity and Learning Deficits in Fragile X Model

    ANAVEX 2-­‐73™ Significantly Reverses the Hyperac2vity and Deficits in Learning and Memory in Fragile X – Au2sm-­‐Related Disorders Model AV2-­‐73 Reverses Hyperac2vity of AV2-­‐73 Normalizes the Impairment in AV2-­‐73 Reduces Impairments in Fmr1-­‐KO2 mice to Normal Associa2ve Learning Characteris2c

  15. Slide 15: Infantile Spasms

    Slide 15: Infantile Spasms

    Infan2le Spasms § A rare yet devasta8ng condi8on, infan8le spasms (IS) is a seizure disorder that typically occurs during the first 4-­‐11 months of childhood § Children who develop IS are at great risk for developmental disability and au8sm § Most children who have infan8le spasms will have a ver

  16. Slide 16: Preclinical Infantile Spasms

    Slide 16: Preclinical Infantile Spasms

    Preclinical Infan2le Spasms § The infan8le spasms rat model represents a clinically relevant animal model of infan8le spasms since the phenotype is developmentally specific and semiologically similar to human infan8le spasms, including clustering of spasms# § The phenotype of spasms persists only u

  17. Slide 17: ANAVEX 2-73 Reduces Number of Spasms in Infant Rat Model

    Slide 17: ANAVEX 2-73 Reduces Number of Spasms in Infant Rat Model

    ANAVEX 2-­‐73™ Significantly Reduces the Number of Spasms in an Infant Rat Model of Infan2le Spasms Treatment with ANAVEX 2-­‐73 significantly reduced the number of spasms by 55 percent compared to vehicle (p=0.0002) 17

  18. Slide 18: Rett Syndrome

    Slide 18: Rett Syndrome

    Re9 Syndrome What is Re9 Syndrome? § Rare non-­‐inherited gene8c postnatal progressive neurodevelopmental disorder § Caused by muta8on of MECP2 gene § Occurs almost exclusively in girls and leads to severe impairments § One in 10,000 to 15,000 girls § Seizures § Anxiety disorder § Cogni8ve im

  19. Slide 19: Preclinical Rett Syndrome

    Slide 19: Preclinical Rett Syndrome

    Preclinical Re9 Syndrome Breeding info § Female mice with heterozygous (HET) MECP2-­‐null muta8on# § A mouse with a MECP2-­‐null muta8on causes neurological symptoms that mimic ReP syndrome § Breeding done at Jackson Laboratories, mice provided at 4-­‐5 weeks of age MECP2 females tes2ng at 8 and

  20. Slide 20: Clasping

    Slide 20: Clasping

    Clasping § Mice are li{ed gently by the tail with front limbs remaining on surface § Clasping of hind legs is noted (normal is a spread in the hind legs) Normal Impaired 20

  21. Slide 21: Clasping at 8 and 12 Weeks

    Slide 21: Clasping at 8 and 12 Weeks

    Clasping at 8 and 12 Weeks § Vehicle-­‐treated mutant (HET) mice clasped more than vehicle-­‐treated wild type (WT) mice (p<0.001 at 8 weeks; p<0.01 at 12 weeks) § Mice treated with AV2-­‐73 (30 mg/kg) clasped less than vehicle-­‐treated mutant mice (p<0.05 at 8 and 12 weeks) Clasping at 8 weeks C

  22. Slide 22: Startle

    Slide 22: Startle

    Startle § The acous8c startle measures an uncondi8oned reflex response to external auditory s8mula8on § Wild type mice have a higher startle response compared to impaired mice Image: www.med-associates.com Source: PsychoGenics, Inc. 22

  23. Slide 23: Startle at 8 Weeks

    Slide 23: Startle at 8 Weeks

    Startle at 8 Weeks § Vehicle-­‐treated mutant (HET) mice startled less compared to vehicle-­‐ treated wild type (WT) mice (p<0.001) § AV2-­‐73 (30 mg/kg) treated mice showed an increased startle response compared to vehicle-­‐treated mutant mice (p<0.05) 600 500 p<0.001 p<0.05 Mean Startle Respons

  24. Slide 24: Rotarod

    Slide 24: Rotarod

    Rotarod Source: PsychoGenics, Inc. 24

  25. Slide 25: Rotarod at 12 Weeks

    Slide 25: Rotarod at 12 Weeks

    Rotarod at 12 Weeks § Vehicle-­‐treated mutant (HET) mice fell significantly more rapidly and at lower speeds compared to vehicle-­‐treated wild type (WT) mice (p<0.001) § AV2-­‐73-­‐treated mice at both doses (10 and 30 mg/kg) took significantly more 8me to fall off the rod and fell at higher speeds

  26. Slide 26: NeuroCube

    Slide 26: NeuroCube

    NeuroCube § A pla|orm that employs computer vision to detect changes in gait geometry and gait dynamics in rodent models of neurological disorders, pain & neuropathies § Mice are allowed to walk in the chamber for 5 min § When the paw touches the screen, LED light reflects crea8ng bright spots §

  27. Slide 27: NeuroCube Body Motion Features

    Slide 27: NeuroCube Body Motion Features

    NeuroCube Body Mo2on Features B ody Movement Features Measurement 120 110 100 Amplitude 90 Shift 80 70 § Shi{ – the difference between the first 60 and the last values § Amplitude – the difference between 50 maximal and minimal values § Vola8lity = Shi{ / Amplitude 40 MinDia 500 550 600 650 700 750

  28. Slide 28: NeuroCube at 8 Weeks

    Slide 28: NeuroCube at 8 Weeks

    NeuroCube at 8 Weeks Some gait differences appear to be rescued p<0.05 p<0.05 70 p<0.01 38 p<0.05 * * F ro n t S te p L e n g th (m m ) S tr id e L e n g th (m m ) 36 60 ** * 34 50 32 40 30 M e c p 2 _ W T V e h ic le M e c p 2 _ H E T V e h icle M e c p 2 _ W T V e h ic le M e c p 2 _ H E T V e h ic

  29. Slide 29: NeuroCube at 8 Weeks: Comprehensive Analysis

    Slide 29: NeuroCube at 8 Weeks: Comprehensive Analysis

    NeuroCube at 8 Weeks Comprehensive Analysis: Gait, Correla2on, Body Mo2on demonstrate significant improvement WT vehicle v. Het vehicle v. Het vehicle v. Het vehicle Het AV2-­‐73, 10 mg/kg Het AV2-­‐73, 30 mg/kg Overall 90, p=0 53, p> 0.69 62, p> 0.24 GAIT 78, p< 0.01 63, p> 0.09 69, p< 0.05 Paw Feat

  30. Slide 30: Summary

    Slide 30: Summary

    Summary § Administra8on of ANAVEX 2-­‐73 results in both significant and dose related improvements in an array of behavioral paradigms in the MECP2 HET ReP syndrome disease model § These behavioral paradigms measure different aspects of muscular coordina8on, balance, motor learning and muscular stre

Source: Internet Archive copy of anavex.com

More decks from Anavex Life Sciences Corp.

All 35 Anavex Life Sciences decks